Strata Critical Medical Inc

Análisis de la acción Strata Critical Medical Inc (SRTA)

$4.660

-0.049 (-1.06%)Al cierre

Loading chart…
Máximo
4.680
Apertura
4.670
Precio medio ponderado por volumen
4.62
Volumen
450.36K
Capitalización
—
Mínimo
4.530
Importe
2.08M
EV/EBITDA, TTM
-93.61

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its segments include Logistics and Clinical. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient.

stratacritical.com

Análisis de IA of Strata Critical Medical Inc (SRTA)

Comprar

Strata Critical Medical Inc (SRTA) is a good buy right now due to its recent strong earnings report showing a 15.1% sequential increase in clinical revenue for Q2 2026, reaching $24.3 million, and an upgraded EBITDA guidance of $33 million to $35 million for the year. The current price of $4.66 is attractive given the potential for significant upside, especially considering the projected trajectory based on similar historical patterns, which indicates a potential increase of 424.67%. However, investors should be cautious of the negative net income trend, with a reported loss of $10.5 million in Q2 2026, which poses a risk to profitability.

Métricas de valoración

El PER previsto actual de Strata Critical Medical Inc (SRTA) es 138.89, frente a su media de 5 años de 70.30.

PER previsto

Valor razonable
Media 5A P/E
70.30
P/E actual
138.89
Sobrevalorada
149.36
Infravalorada
-8.76

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
90.84
EV/EBITDA actual
-93.61
Sobrevalorada
349.26
Infravalorada
-167.58

Precio/ventas previsto

Valor razonable
Media 5A P/S
1.41
P/S actual
1.28
Sobrevalorada
1.64
Infravalorada
1.18

Ballenas con SRTA en cartera

T

Third Point LLC

+ Con en carteraSRTA

-3.98%

Rentabilidad a 3 meses

Cronología de eventos

2026-05-06 (ET)

07:40:00

Company Reports Q1 Revenue of $67.38M, Exceeding Expectations

07:40:00

Strata Adjusts FY26 EBITDA Guidance to $29M-$33M

2026-03-03 (ET)

07:10:00

Raises EBITDA Outlook to $29M-$33M

07:10:00

Will Heyburn: Company Aims for 30% Annual EBITDA Growth

2026-02-05 (ET)

08:50:00

Strata Critical Medical Enters $30M Credit Agreement with JPMorgan

Noticias

Preguntas frecuentes sobre SRTA, respondidas por Alphio AI

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its segments include Logistics and Clinical. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient. It operates in the Industrials sector.

Strata Critical Medical Inc (SRTA) is a good buy right now due to its recent strong earnings report showing a 15.1% sequential increase in clinical revenue for Q2 2026, reaching $24.3 million, and an upgraded EBITDA guidance of $33 million to $35 million for the year. The current price of $4.66 is attractive given the potential for significant upside, especially considering the projected trajectory based on similar historical patterns, which indicates a potential increase of 424.67%. However, investors should be cautious of the negative net income trend, with a reported loss of $10.5 million in Q2 2026, which poses a risk to profitability.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar